Navigation Links
Aeterna Zentaris Reports First Quarter 2010 Financial and Operating Results
Date:5/13/2010

--------------------------------------------- $ $ Cash and cash equivalents 26,947 38,100 Accounts receivable and other current assets 10,383 10,913 Restricted cash 833 878 Property, plant and equipment 3,885 4,358 Other long-term assets 29,924 32,013 ------------------------------------------------------------------------- Total assets 71,972 86,262 ------------------------------------------------------------------------- ------------------------------------------------------------------------- Accounts payable and other current liabilities 14,777 19,211 Current portion of long-term payable 59 57 Long-term payable 118 143 Non-financial long-term liabilities* 53,848 57,625 ------------------------------------------------------------------------- Total liabilities 68,802 77,036 Shareholders' equity 3,170 9,226 ------------------------------------------------------------------------- Total liabilities and shareholders' equity 71,972 86,262 ------------------------------------------------------------------------- ------------------------------------------------------------------------- * Comprised mainly of deferred revenues and employee future benefits.


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Aeterna Zentaris: FDA Approves Investigational New Drug (IND) Application for Doxorubicin Targeted Conjugate Compound, AEZS-108, in Bladder Cancer
2. Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer
3. AEterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Benign Prostatic Hyperplasia
4. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
5. AEterna Zentaris Announces Appointment of New Board Member
6. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
7. AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia
8. AEterna Zentaris Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma
9. AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer
10. AEterna Zentaris Receives US$5.5 Million from Institutional Investors
11. AEterna Zentaris to Raise US$5.5 Million from Institutional Investors at US$1.20 Per Share
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... 21, 2015 Immune Pharmaceuticals Inc., or "Immune" ... Directors has elected Rene-Pierre Azria as a ... Committee, with oversight on strategic and financial transactions. Mr. ... Committee, the Compensation Committee and the Corporate Governance and ... commented: "I have a long-time interest in Life Sciences ...
(Date:4/21/2015)... , April 21, 2015  Novogen Limited (ASX:NRT; ... biotechnology company, advises that it has entered into ... fully-paid ordinary shares plus one attaching 6-month option ... every ordinary share issued, to institutional investors in ... a private placement for aggregate gross proceeds of ...
(Date:4/21/2015)... April 21, 2015 Leading-edge ... clinical applications will be presented at the ... scientists, regulators and clinicians from academia, industry ... sponsored by Invibio Biomaterial Solutions. The world-leading ... specialist in manufacturing and R&D for medical-device ...
(Date:4/20/2015)... April 20, 2015 Stent retriever thrombectomy, ... vessels in the brain reduced disability after stroke, ... Jovin, MD, President of the Society of Vascular ... is a giant step forward that will change ... stroke patients," said Jovin, who is associate professor ...
Breaking Biology Technology:Immune Board Elects Rene-Pierre Azria A Director And Chair Of The Transaction Committee 2Immune Board Elects Rene-Pierre Azria A Director And Chair Of The Transaction Committee 3Immune Board Elects Rene-Pierre Azria A Director And Chair Of The Transaction Committee 4Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 2Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 3Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 4Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 5Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 62nd International PEEK Meeting: Invibio Biomaterial Solutions spearheads medical research for implantable PEEK polymer devices 22nd International PEEK Meeting: Invibio Biomaterial Solutions spearheads medical research for implantable PEEK polymer devices 3SVIN President Tudor Jovin, MD, Co-Leads Groundbreaking Stroke Study In The New England Journal Of Medicine 2SVIN President Tudor Jovin, MD, Co-Leads Groundbreaking Stroke Study In The New England Journal Of Medicine 3
... CV Therapeutics,Inc. (Nasdaq: CVTX ) today announced ... results for 2007 after the market closes on Tuesday,February ... at,5:00 p.m. EST, 2:00 p.m. PST, on the company,s ... on to the Company,s website at, http://www.cvt.com and ...
... In a letter to,Governor Jennifer Granholm today, ... Governor,s State of the State Address,wherein she called ... is the,statewide association for Michigan,s life sciences industry., ... the legislature, to diversify,the state,s economy by focusing ...
... Md., Jan. 30 MiddleBrook,Pharmaceuticals, Inc. (Nasdaq: ... commercializing novel anti-infective products, today,announced that it has ... and warrants, resulting in the receipt of $21 ... use the proceeds from the financing to support,the ...
Cached Biology Technology:CV Therapeutics to Announce 2007 Fourth Quarter and Year End Financial Results on Tuesday, February 26, 2008 2MichBio Responds to Governor's Plan to Repeal Tort Reform Laws 2MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million 2MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million 3
(Date:4/14/2015)... April 14, 2015  HYPR Corp. today announced ... ® ) Alliance tm , an industry consortium ... commit to share technology and collaborate to deliver ... interoperable, more secure and private, and easier to ... verification that protects sensitive user information and eliminates ...
(Date:4/10/2015)... , April 10, 2015 Research ... of the "Security Competitive Profiles - NEC" ... , NEC will continue to supply a ... the market, with a company focus on the development ... Winning opportunities in the Asia-Pacific ...
(Date:4/2/2015)... , April 2, 2015 ... DERMALOG by far outperforms the strongest competitors, showing ... high accuracy, the system is capable of a ... speed proves up to be ten times faster ... its runner-up performance.      (Photo: ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3NEC Security Competitive Profile 2015 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... that acts as a "master switch" in certain white ... The study, published in the journal Nature Immunology ... diseases such as rheumatoid arthritis that involve excessive inflammation. ... body uses against harmful stimuli such as infections or ...
... WASHINGTON, Jan. 15, 2011 In research described as "a ... reporting that cigarette smoke begins to cause genetic damage within ... Their report, the first human study to detail the ... cancer, appears in Chemical Research in Toxicology , one ...
... 2010) The kidney is made up of roughly 1 ... waste products from the blood, recycle some substances to be ... segment of nephrons, called the distal nephron, helps set blood ... Today scientists at The University of Texas Health ...
Cached Biology News:Scientists find the 'master switch' for key immune cells in inflammatory diseases 2'A stark warning:' Smoking causes genetic damage within minutes after inhaling 2
... Immunogen KLH-conjugated, synthetic ... 54-75 (RRGPHRNPG-PGDDDGQRSRSSS) of mouse p19ARF. ... to amino acids 62-75. Clone ... Routinely evaluated by immunoblot. ...
EDG-1 Western blot control Source: Cell Lysate Application: Western Blotting Control...
Complete cell culture media with cytokines...
...
Biology Products: